Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

被引：8

作者：

Spurgeon, Stephen E. ^{[1
]}

Mei, Matthew ^{[2
]}

Barr, Paul M. ^{[3
]}

Barrientos, Jacqueline C. ^{[4
]}

de Vos, Sven ^{[5
]}

Furman, Richard R. ^{[6
]}

Patel, Krish ^{[7
]}

Thompson, Philip A. ^{[8
]}

Choi, Michael Y. ^{[9
]}

Kallam, Avyakta ^{[10
]}

Wang, Sirou ^{[11
]}

Ogbu, Uzor C. ^{[11
]}

Nahar, Akash ^{[11
]}

Wang, Michael L. ^{[8
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[2] City Hope Natl Med Ctr, Duarte, CA USA

[3] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[4] Mt Sinai Med Ctr, Miami, FL USA

[5] UCLA Hematol Oncol, Santa Monica, CA USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Swedish Med Ctr, Seattle, WA USA

[8] MD Anderson Canc Ctr, Houston, TX USA

[9] Univ Calif San Diego, La Jolla, CA 92093 USA

[10] Univ Nebraska Med Ctr, Omaha, NE USA

[11] Merck & Co Inc, Rahway, NJ 07065 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163509

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6640 / 6641

页数：2

共 50 条

[1] Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma
Wang, Michael
Mei, Matthew
Barr, Paul M.
Barrientos, Jacqueline
de Vos, Sven
Furman, Richard
Patel, Krish
Thompson, Philip A.
Choi, Michael
Kallam, Avyakta
Zhu, Ying
Chakraborty, Samhita
Marinello, Patricia
Spurgeon, Stephen E.
BLOOD, 2021, 138
[2] Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study
Ozcan, Muhit
Lv, Fangfang
Norasetthada, Lalita
Paszkiewicz-Kozik, Ewa
Schmidt, Joaquin Diaz
Modi, Dipenkumar
Fossa, Alexander
Goyal, Sagun
Kim, Won Seog
Lee, Seung Tae
Santoro, Armando
Sonmez, Mehmet
Pathiraja, Kumudu
Reddy, Nishitha
Marinello, Patricia
Song, Yuqin
BLOOD, 2023, 142
[3] Updated Follow-Up of the Phase 1waveLINE-001 Study of Zilovertamab Vedotin in Relapsed or Refractory (R/R) NonHodgkin Lymphoma (NHL)
Michael, Wang L.
Mei, Matthew
Paul, Barr M.
Jacqueline, Barrientos C.
de Vos, Sven
Richard, Furman R.
Patel, Krish
William, Wierda G.
Michael, Choi Y.
Kallam, Avyakta
Wang Siruo
Uzor, Ogbu C.
Marinello, Patricia
Stephen, Spurgeon E.
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S52 - S52
[4] Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
Ozcan, Muhit
Lee, Seung Tae
Mensah, Felix
Modi, Dipenkumar
Fossa, Alexander
Kim, Won Seog
Paszkiewicz-Kozik, Ewa
Sawalha, Yazeed
Sevindik, Omur Gokmen
Norasetthada, Lalita
Santoro, Armando
Pathiraja, Kumudu
Chakraborty, Samhita
Marinello, Patricia
Lavie, David
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Morschhauser, Franck
Flinn, Ian
Advani, Ranjana H.
Diefenbach, Catherine S.
Kolibaba, Kathryn
Press, Oliver W.
Sehn, Laurie H.
Chen, Andy I.
Salles, Gilles
Tilly, Herve
Cheson, Bruce D.
Assouline, Sarit
Dreyling, Martin
Hagenbeek, Anton
Zinzani, Pier Luigi
Yalamanchili, Sreeni
Lu, Dan
Jones, Cheryl
Jones, Surai
Chu, Yu-Waye
Sharman, Jeff P.
BLOOD, 2014, 124 (21)
[6] Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.
Advani, Ranjana
Oki, Yasuhiro
Shustov, Andrei R.
Grove, Laurie E.
Bartlett, Nancy
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[7] Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study
Kinoshita, Tomohiro
Hatake, Kiyohiko
Yamamoto, Kazuhito
Higuchi, Yusuke
Murakami, Satsuki
Terui, Yasuhito
Yokoyama, Masahiro
Maruyama, Dai
Makita, Shinichi
Hida, Yukari
Saito, Tomohisa
Tobinai, Kensei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (01) : 70 - 77
[8] Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study
Michot, Jean-Marie
Bouabdallah, Reda
Vitolo, Umberto
Doorduijn, Jeanette K.
Salles, Gilles
Chiappella, Annalisa
Zinzani, Pier Luigi
Bijou, Fontanet
Kersten, Marie Jose
Sarmiento, Rafael
Mosulen, Silvia
Mendez, Cristina
Uttamsingh, Shailaja
Pourdehnad, Michael
Hege, Kristen
Chen, Tianlei
Klein, Christian
Hagner, Patrick R.
Nikolova, Zariana
Ribrag, Vincent
LANCET HAEMATOLOGY, 2020, 7 (09): : E649 - E659
[9] Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Nastoupil, Loretta J.
Lunning, Matthew A.
Vose, Julie M.
Schreeder, Marshall T.
Siddiqi, Tanya
Flowers, Christopher R.
Cohen, Jonathon B.
Burger, Jan A.
Wierda, William G.
O'Brien, Susan
Sportelli, Peter
Miskin, Hari P.
Purdom, Michelle A.
Weiss, Michael S.
Fowler, Nathan H.
LANCET HAEMATOLOGY, 2019, 6 (02): : E100 - E109
[10] Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Morschhauser, Franck
Flinn, Ian W.
Advani, Ranjana
Sehn, Laurie H.
Diefenbach, Catherine
Kolibaba, Kathryn
Press, Oliver W.
Salles, Gilles
Tilly, Herve
Chen, Andy I.
Assouline, Sarit
Cheson, Bruce D.
Dreyling, Martin
Hagenbeek, Anton
Zinzani, Pier Luigi
Jones, Surai
Cheng, Ji
Lu, Dan
Penuel, Elicia
Hirata, Jamie
Wenger, Michael
Chu, Yu-Waye
Sharman, Jeff
LANCET HAEMATOLOGY, 2019, 6 (05): : E254 - E265

← 1 2 3 4 5 →